Wednesday, July 8, 2026

Patent intelligence · US

US 11541177

Injection spring for aged prefilled syringe and auto injector

granted A61PA61P25/06
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 454
Patent details — US 11541177

Quick answer

US 11541177 (Injection spring for aged prefilled syringe and auto injector) is held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH. Status: granted. Granted Jan 3, 2023. Expires Dec 29, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
19
CPC classes
A61P, A61P25/06

More from TEVA PHARMACEUTICALS INTERNATIONAL GMBH

Related pharmaceutical patents in our USPTO index.

  1. US 12310929

    Use of rasagiline for the treatment of restless legs syndrome

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Expires May 22, 2045

    granted
  2. US 12258401

    Anti-CD47 combination therapy

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Expires Mar 20, 2045

    granted
  3. US 12157729

    Solid state forms of Belumosudil and Belumosudil salts

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Expires Nov 28, 2044

    granted
  4. US 12139528

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Expires Nov 7, 2044

    granted
  5. US 12091388

    Solid state forms of Reproxalap

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Expires Sep 12, 2044

    granted
  6. US 11826322

    Pre-filled syringe

    Teva Pharmaceuticals USA, Inc. · Expires Nov 23, 2043

    granted
  7. US 11813359

    Sustained release olanzapine formulations

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Expires Nov 9, 2043

    granted
  8. US 11773083

    Solid state forms of Belumosudil and Belumosudil salts

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Expires Sep 28, 2043

    granted

Frequently asked questions

What is US patent 11541177?

US 11541177 (Injection spring for aged prefilled syringe and auto injector) is held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH. Status: granted. Granted Jan 3, 2023. Expires Dec 29, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11541177?

TEVA PHARMACEUTICALS INTERNATIONAL GMBH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.

When does US 11541177 expire?

Our index shows an expiration date of Dec 29, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.